Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Mulhearn

Interventional Cardiology Lake Charles, LA Medical Doctor

NPI 1285789008 CMS profile 148827

600 Dr Michael Debakey Dr, Lake Charles, LA 70601

Open in the dashboard

General payments

$4,744

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,039 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Thomas Mulhearn of Lake Charles, LA is reported in the CMS Open Payments database as having received $4,744 across 230 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,039 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 37th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $592 29
2024 General $697 30
2023 General $996 47
2022 General $876 43
2021 General $307 17
2020 General $232 12
2019 General $1,044 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Mulhearn
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Thomas Mulhearn were reported at $592. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Thomas Mulhearn Interventional Cardiology median Middle half National median
2019 $1,044 $1,097 $329–$3,048 $163
2020 $232 $473 $161–$1,480 $114
2021 $307 $677 $233–$1,827 $132
2022 $876 $978 $333–$2,724 $149
2023 $996 $1,136 $382–$2,986 $160
2024 $697 $1,181 $395–$3,326 $164
2025 $592 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $662 43 payments
  2. Novartis Pharmaceuticals Corporation $598 40 payments
  3. E.R. Squibb & Sons, L.L.C. $488 34 payments
  4. Boston Scientific Corporation $472 16 payments
  5. Medtronic, Inc. $411 8 payments
  6. Janssen Pharmaceuticals, Inc $358 24 payments
  7. Abbott Laboratories $286 9 payments
  8. Edwards Lifesciences Corporation $229 3 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $157 10 payments
  10. Cleerly, Inc. $117 1 payment
  11. Other $968 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,744 230 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $652 42 payments
  2. XARELTO $358 24 payments
  3. LEQVIO $301 19 payments
  4. ELIQUIS Cardiovascular $280 20 payments
  5. CAMZYOS $208 14 payments
  6. ENTRESTO $194 14 payments
  7. WATCHMAN Access System $188 7 payments
  8. LifeVest $157 10 payments
  9. COREVALVE EVOLUT R $149 2 payments
  10. Ensite Cardiac Mapping System $136 1 payment
  11. Other $2,305 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

5,651

Median for Interventional Cardiology: 2,236

Drug cost

$938,787

Median for Interventional Cardiology: $380,412

Branded share of claims

29.1%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 582 $533,758
Xarelto Rivaroxaban Brand 200 $139,203
Entresto Sacubitril/Valsartan Brand 85 $84,991
Repatha Sureclick Evolocumab Brand 84 $59,661
Farxiga Dapagliflozin Propanediol Brand 34 $25,278
Droxidopa Generic 15 $18,160
Nexletol Bempedoic Acid Brand 23 $8,874
Nexlizet Bempedoic Acid/Ezetimibe Brand 15 $8,218
Atorvastatin Calcium Generic 572 $6,204
Metoprolol Succinate Generic 449 $6,044

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 154 billing codes

Paid by Medicare

$1,137,742

Of which drugs: $3,919

Medicare patients

2,193

Average age 75

Services billed

14,145

1,131 women, 1,062 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Arthritis 57%
Diabetes 40%
Chronic kidney disease 35%
Heart failure 34%
Atrial fibrillation 33%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 185 752 $3,919

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $81
$81 — —
ELIQUIS
  • PFIZER INC. $37
  • E.R. Squibb & Sons, L.L.C. $29
$66 582 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $49
$49 85 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $46
$46 — —
NURTEC ODT
  • PFIZER INC. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record